Citations

Clear

30 citation(s) found for "Saw, J".

Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis
Samaras, Athanasios , Balomenakis, Charalampos , Moysidis, Dimitrios V. , Patsiou, Vasiliki , Orfanidis, Antonios, Saw, Jacqueline , Landmesser, Ulf , Alkhouli, Mohamad Adnan, Tzikas, Apostolos , Moysidis, Dimitrios V , Saw, Jacqueline , Landmesser, Ulf , Tzikas, Apostolos , Samaras, Athanasios , Papazoglou, Αndreas S. , Bekiaridou, Αlexandra , Giannakoulas, George , Kassimis, George , Fragakis, Nikolaos

Mayo Clinic

European Heart Journal | December 1, 2023 | Volume: 45 | Issue: 3 | Pages: 214-229

10.1093/eurheartj/ehad828 | PMID 38088437 Get It

Abstract Background and Aims Residual leaks are not infrequent after left atrial appendage occlusion. However, there is still uncertainty regarding their prognostic implications. The aim of this study is to evaluate the impact of residual leaks after left atrial appendage occlusion. Methods A literature search was conducted until 19 February 2023. Residual leaks comprised peri-device leaks (PDLs) on transoesophageal echocardiography (TEE) or computed tomography (CT), as well as left atrial appendage patency on CT. Random-effects meta-analyses were performed to assess the clinical impact of residual leaks. Results Overall 48 eligible studies (44 non-randomized/observational and 4 randomized studies) including 61 666 patients with atrial fibrillation who underwent left atrial appendage occlusion were analysed. Peri-device leak by TEE was present in 26.1% of patients. Computed tomography-based left atrial appendage patency and PDL were present in 54.9% and 57.3% of patients, respectively. Transoesophageal echocardiography-based PDL (i.e. any reported PDL regardless of its size) was significantly associated with a higher risk of thromboembolism [pooled odds ratio (pOR) 2.04, 95% confidence interval (CI): 1.52–2.74], all-cause mortality (pOR 1.16, 95% CI: 1.08–1.24), and major bleeding (pOR 1.12, 95% CI: 1.03–1.22), compared with no reported PDL. A positive graded association between PDL size and risk of thromboembolism was noted across TEE cut-offs. For any PDL of >0, >1, >3, and >5 mm, the pORs for thromboembolism were 1.82 (95% CI: 1.35–2.47), 2.13 (95% CI: 1.04–4.35), 4.14 (95% CI: 2.07–8.27), and 4.44 (95% CI: 2.09–9.43), respectively, compared with either no PDL or PDL smaller than each cut-off. Neither left atrial appendage patency, nor PDL by CT was associated with thromboembolism (pOR 1.45 and 1.04, 95% CI: 0.84–2.50 and 0.52–2.07, respectively). Conclusions Peri-device leak detected by TEE was associated with adverse events, primarily thromboembolism. Residual leaks detected by CT were more frequent but lacked prognostic significance.
Abstract 12681: GWAS Meta-Analysis in SCAD, a Women Predominant Ischemic Heart Disease, Reveals Common Variants and Genes Related to Artery Integrity and Tissue-Mediated Coagulation
Adlam, David , Ma, Lijiang , Blencowe, Montgomory, Turley, Tamiel N. , Yang, Min‐Lee , Junday, Keerat , CARDIoGRAMPlusC4D, investigators, DISCO register, Saw, Jacqueline , Xia, Yang, Samani, Nilesh J. , Berrandou, Takiy-Eddine , Georges, Adrien , Nelson, Christopher P. , Giannoulatou, Eleni , Iismaa, Siiri E. , Tarr, Ingrid S. , Muller, David W. , Hesselson, Stephanie , Fatkin, Diane , CARDIoGRAMPlusC4D, Combaret, Nicolas , investigators, DISCO register, Webb, Tom R. , Tweet, Marysia S. , Hayes, Sharonne N. , Yang, Xia , Ganesh, Santhi K. , Olson, Timothy M. , Kovacic, Jason C. , Graham, Robert M. , Bouatia‐Naji, Nabila

Mayo Clinic

Circulation | June 15, 2023 | Volume: 146 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.146.suppl_1.12681 Get It

Introduction: Spontaneous coronary artery dissection (SCAD) is an understudied cause of acute myocardial infarction due to hematoma formation in coronary arteries primarily affecting women. It is not known to what extent SCAD is genetically distinct from other cardiovascular diseases, including atherosclerotic coronary artery disease (CAD). Methods and Results: Through a meta-analysis of 8 GWAS (1917 cases, 9292 controls of European ancestry), we identified 17 risk loci, including 12 new. Functional annotations pointed at enrichment in enhancer marks of arteries, specifically smooth muscle cells, and strong candidate genes, such as tissue factor gene ( F3 ) on Chr1 near rs1146473 (OR=1.32, P=5.8 х10 -9 ). F3 is novel for SCAD or any cardiovascular disease. The risk allele correlated with F3 lower expression in arteries, supporting a mechanism consistent with hematoma formation. Bayesian gene regulatory networks constructed from expression and genetics data indicated the extracellular matrix organization in arteries as the biological function where most prioritized genes clustered (e.g. COL4A1/A2, HTRA1, and TIMP3 ). Overall, we report substantial polygenicity for SCAD (LDSC: h 2 SNP = 0.71 ± 0.11) and shared genetics with several neurovascular diseases (e.g intracranial aneurysm). Intriguingly, for 6 loci, colocalization analyses showed that SCAD and CAD are likely to share the same causal variants but involve opposite risk alleles (e.g COL4A1/A2 ). In addition, a negative genetic correlation was found between SCAD and CAD (rg=-0.12; P=3.7х10 -3 ), including after conditioning on BP (mt-COJO: rg CAD/SBP =-0.19, P=4.6х10 -6 ). Mendelian randomization analyses indicated higher BP to associate with increased risk for SCAD (beta IVW-SBP =0.05, P=7.6х10 -6 , beta IVW-DBP =0.10, P=1.9х10 -6 ) and CAD (beta IVW-SBP =0.04, P=8.6х10 -49 ; DBP: beta IVW-DBP =0.06, P=1.6х10 -44 ) but not BMI, lipids, or type 2 diabetes, which we confirmed as genetic risk factors for CAD Conclusions: Our results set the stage for future investigation of novel biological pathways relevant to both SCAD and CAD and potential therapeutic and preventive strategies specifically targeting this ischemic disease predominantly affecting women.
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
DePalo, Danielle K. , Naqvi, Syeda Mahrukh Hussnain , Ollila, David W. , Block, Matthew S. , Duncan, Zoey , Anderson, Matilda, Vetto, John T. , Saw, Robyn P.M. , Lo, Serigne , Akkooi, Alexander Christopher Jonathan Van, Akkooi, Alexander C. J. van , Lo, Serigne N , Hieken, Tina J. , Houdt, Winan J. van , Wouters, Michel W.J.M. , Asher, Nethanel , Broman, Kristy K. , Gyorki, David E. , Hui, Jane Yuet Ching , Kim, Youngchul , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 9574-9574

10.1200/jco.2023.41.16_suppl.9574 Get It

9574 Background: Surgery remains the gold standard for resectable melanoma in-transit metastases (ITM). Unresectable ITM is a heterogenous disease with multiple treatment (tx) options including systemic therapies such as immune checkpoint inhibitors (ICI), regional therapies such as isolated limb infusion or perfusion (ILI/P), and intratumoral therapies such as talimogene laherparepvec (IT). Until now, there has been no direct comparison of these first-line tx for unresectable ITM. Methods: A retrospective chart review of patients (pts) with ITM treated first-line with IT, ILI/P, or ICI was performed at 11 institutions. Pts with unresectable ITM, synchronous nodal or distant metastatic disease were excluded. Results: 560 pts (54% women) were identified, 86 received IT, 353 received ILI/P, and 121 received ICI from 1990-2022. ICI pts were youngest, IT pts were oldest (p<0.001). Limb was the most common site of ITM. There was no difference in largest ITM size, but number of lesions (burden of disease (BOD)) was highest in ILI/P pts and lowest in IT pts (p=0.003). Toxicity (tox) requiring <90 days (p<0.001) or > 90 days (p=0.034) of pharmacologic tx as well as tox requiring hospitalization (p<0.001) was greatest in ICI pts. Lymphedema was more likely in ILI/P pts (p=0.016). Median follow-up was much longer for ILI/P pts at 8.0 yrs compared to 2.5 yrs for IT pts and 3.1 yrs for ICI pts. Overall response rate (ORR) was 82.2% in ILI/P pts, significantly higher than IT (72.1%, p=0.047) or ICI pts (63.6%, p<0.001). Overall survival was similar between modalities (p=0.167); however, ILI/P pts had worse progression-free survival (PFS) (p<0.0001) and melanoma-specific survival (MSS) (p=0.003). On multivariable analysis of MSS by number of ITM present, MSS remained worst if ILI/P was used for low BOD, ≤3 ITM (p=0.005), but no difference was seen between tx modalities for higher BOD, >3 ITM (p=0.211). Conclusions: ICI was used more often in younger pts with less BOD, IT in older pts with less BOD, and ILI/P in older pts with high BOD. Short and long-term tox was greater in ICI. ILI/P had the best ORR, but ICI and IT resulted in greater overall MSS. Multidisciplinary consideration of risks and benefits of each modality should guide ITM tx selection. [Table: see text]
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury
Cheng, Jinping , Jiang, Jingru, He, Baixuan, Lin, Wei‐Jye , Li, Yi , Li, Honghong , Huang, Xiaolong , Xie, Jiatian, Zhang, Zhan , Yang, Yuhua , Xu, Yongteng , Hu, Xia , Wu, Minyi, Zhuo, Xiaohuang , Pei, Yu , Rong, Xiaoming , Ye, Xiaojing , Saw, Phei Er , Wu, Long‐Jun , Mai, Hai‐Qiang , Tang, Yamei , Li, Honghong , Zhang, Zhan , Xu, Yongteng , Shi, Zhongshan , Ye, Xiaojing , Saw, Phei Er , Wu, Long-Jun , Simone, Charles B , Chua, Melvin L K , Tang, Yamei , Duan, Jingjing, Cai, Jinhua , Hu, Xia, Liu, Qiang , Yu, Pei, Simone, Charles B. , Chua, Melvin L.K. , Mai, Hai‐Qiang

Mayo Clinic

Science Translational Medicine | February 22, 2023 | Volume: 15 | Issue: 684 | Pages: No page available

10.1126/scitranslmed.abm6543 | PMID 36812346 Get It

Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a Simon’s minmax two-stage, single-arm, phase 2 clinical trial (NCT03208413) to assess the efficacy of thalidomide in patients with RIBI who were unresponsive to or had contraindications to bevacizumab and corticosteroid therapies. The trial met its primary endpoint, with 27 of 58 patients enrolled showing ≥25% reduction in the volume of cerebral edema on fluid-attenuated inversion recovery–magnetic resonance imaging (FLAIR-MRI) after treatment (overall response rate, 46.6%; 95% CI, 33.3 to 60.1%). Twenty-five (43.1%) patients demonstrated a clinical improvement based on the Late Effects Normal Tissues–Subjective, Objective, Management, Analytic (LENT/SOMA) scale, and 36 (62.1%) experienced cognitive improvement based on the Montreal Cognitive Assessment (MoCA) scores. In a mouse model of RIBI, thalidomide restored the blood-brain barrier and cerebral perfusion, which were attributed to the functional rescue of pericytes secondary to elevation of platelet-derived growth factor receptor β (PDGFRβ) expression by thalidomide. Our data thus demonstrate the therapeutic potential of thalidomide for the treatment of radiation-induced cerebral vasculature impairment.
Cardiac computed tomography following Watchman FLX implantation: device-related thrombus or device healing?
Kramer, Anders , Korsholm, Kasper , Jensen, Jesper Møller , Nørgaard, Bjarne Linde , Peelukhana, Srikara, Herbst, Thomáš, Horton, Rodney , Kar, Saibal , Saw, Jacqueline , Alkhouli, Mohamad , Nielsen‐Kudsk, Jens Erik , Kramer, Anders Dahl , Alkhouli, Mohamad , Korsholm, Kasper , Møller Jensen, Jesper , Nørgaard, Bjarne Linde , Peelukhana, Srikara Viswanath

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | October 20, 2022 | Volume: 24 | Issue: 2 | Pages: 250-259

10.1093/ehjci/jeac222 | PMID 36336848 Get It

Abstract Aims Cardiac computed tomography (CT) is increasingly utilized during follow-up after left atrial appendage closure (LAAC). Hypoattenuated thickening (HAT) is a common finding and might represent either benign device healing or device-related thrombosis (DRT). The appearance and characteristics of HAT associated with the Watchman FLX have not been previously described. Therefore, we sought to investigate cardiac CT findings during follow-up after Watchman FLX implantation with a focus on HAT and DRT. Methods and results Retrospective single-centre, observational study including all patients with successful Watchman FLX implantation and follow-up cardiac CT between March 2019 and September 2021 (n = 244). Blinded analysis of CT images was performed describing the localization, extent, and morphology of HAT and correlated to imaging and histology findings in a canine model. Relevant clinical and preclinical ethical approvals were obtained. Overall, HAT was present in 156 cases (64%) and could be classified as either subfabric hypoattenuation (n = 59), flat sessile HAT (n = 78), protruding sessile HAT (n = 16), or pedunculated HAT (n = 3). All cases of pedunculated HAT and five cases of protruding sessile HAT were considered as high-grade HAT (n = 7). Subfabric hypoattenuation and flat sessile HAT correlated with device healing and endothelialization in histological analysis of explanted devices. Conclusion Subfabric hypoattenuation and flat sessile HAT are frequent CT findings for Watchman FLX, likely representing benign device healing and endothelialization. Pedunculated HAT and protruding HAT are infrequent CT findings that might represent DRT.
Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry
Daimee, Usama A. , Wang, Yongfei , Masoudi, Frederick A. , Varosy, Paul D. , Du, Chengan, Koutras, Cristina, Saw, Jacqueline , Price, Matthew J. , Curtis, Jeptha P. , Reddy, Vivek Y , Saw, Jacqueline , Price, Matthew J , Kusumoto, Fred M , Curtis, Jeptha P , Freeman, James V , Friedman, Daniel J , Reddy, Vivek Y. , Kusumoto, Fred , Freeman, James V.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 12, 2022 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.121.008418 | PMID 35959677 Get It

Background: The Food and Drug Administration approved left atrial appendage occlusion with the Watchman device for patients who are at increased stroke risk and are suitable for oral anticoagulation but who have an appropriate reason to seek a nondrug alternative. These broad criteria raise the question of their interpretation in clinical practice. There is a lack of studies comprehensively evaluating the indications for Watchman implantation among a large series of patients from contemporary, real-world practice in the United States. Methods: We used the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry to identify Watchman procedures performed between 2016 and 2018. We assessed procedural indications for Watchman implantation in the United States and evaluated the association between procedural indications and in-hospital adverse events. Results: A total of 38 314 procedures were included. The mean patient age was 76.1±8.1 years, and 58.9% were men. The mean CHA 2 DS 2 -VASc score was 4.8±1.5, whereas the mean hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) score was 3.0±1.1. Prior stroke or transient ischemic attack was reported in 40.2% and prior bleeding in 70.1%, with gastrointestinal bleeding being most common (41.9%). The most common site-reported procedural indications for Watchman implantation were increased thromboembolic risk (64.8%) and history of major bleed (64.3%), followed by high fall risk (35.5%). Most (71.9%) had ≥2 procedural indications. Patients with high fall risk had increased risk of in-hospital adverse events (adjusted OR, 1.12; P =0.025), but no other differences were found in the risk of in-hospital adverse events by procedural indication. Conclusions: Among patients in the National Cardiovascular Data Registry Left Atrial Appendage Occlusion Registry, the most common procedural indications for Watchman implantation were increased thromboembolic risk, history of major bleed, and high fall risk. A majority of patients had multiple procedural indications. High fall risk conferred a modestly increased risk of in-hospital adverse events.
Ischiofemoral impingement syndrome provoked by labor: An unusual case of complete sciatic mononeuropathy
Saw, Jacqui‐Lyn , Hale, Jeremy, Madhavan, Ajay A. , Ringler, Michael D. , Toledano, Michel , Madhavan, Ajay A , Hale, Jeremy, Naddaf, Elie

Mayo Clinic

The Neuroradiology Journal | June 19, 2022 | Volume: 36 | Issue: 1 | Pages: 116-118

10.1177/19714009221109895 | PMID 35723073 Get It

Peripheral neuropathies are a recognized complication of labor in the post-partum period. Herein, we describe an uncommon presentation of sciatic mononeuropathy due to ischiofemoral impingement during labor. A 29-year-old, gravida 4 para 2, female presented post-partum with acute left lower limb paresthesia and left foot drop, following spontaneous vaginal delivery of twins. Neurological examination demonstrated no activation of the left sciatic-innervated muscles and sensory loss in the same distribution. Electromyography (EMG) demonstrated an acute complete left sciatic mononeuropathy. MRI of the lumbosacral plexus and sciatic nerve showed a narrowed quadratus femoris space with mild edema of the muscle, consistent with ischiofemoral impingement syndrome. In addition, there was flattening of the sciatic nerve as it passed through the ischiofemoral space. She was treated conservatively, and at 7-month follow-up, there was marked improvement in muscle strength with ongoing sensory impairment. Repeat EMG demonstrated reinnervation in all sciatic-innervated muscles. This case highlights the risk of a sciatic mononeuropathy secondary to ischiofemoral impingement in the peripartum setting. Future studies are needed to determine if women with a narrow ischiofemoral space at baseline are at increased risk for peripheral nerve injury during labor.
Sex‐Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
Madan, Mina , Abbott, J. Dawn , Lennon, Ryan J. , So, Derek , MacDougall, Andrea, McLaughlin, Mary Ann , Murthy, Vishakantha , Saw, Jacqueline , Rihal, Charanjit S. , Farkouh, Michael E. , Pereira, Naveen L. , Abdul‐Nour, Khaled, Dehghani, Payam , Doll, Josh, El‐Hajjar, Mohammed, Ginete, Wilson , Bachuwar, Alok, Graham, John, Guild, Cameron, Campbell, William W., Kostopoulis, Louie, Lane, Gary E. , Marzo, Kevin , O’Cochlain, Fearghas, Overgaard, Christopher B., Dzavik, Vlad, Raveendran, Ganesh , Reimers, Carl D., Garratt, Kirk N. , Saucedo, Jorge , Levisay, Justin , Suresh, D. P., Sweeney, John P., Tiong, Irving, Weitz, Steven, Wu, Alan H.B. , Lennon, Ryan J , So, Derek Y , Rihal, Charanjit S. , Goodman, Shaun G , Dawn Abbott, J , Goodman, Shaun G. , Abdul-Nour, Khaled, Darki, Amir , El-Hajjar, Mohammed C., Escobedo, Jorge , Frank, Adam, Goldberg, Ronald B , Campbell, William, Kim, Sang‐Wook , Lim, Hong‐Seok , Nazif, Tamim , Džavík, Vladimír , Razzouk, Louai , Reimers, Carl, Suresh, D.P., Weitz, Steven

Mayo Clinic

Journal of the American Heart Association | June 14, 2022 | Volume: 11 | Issue: 12 | Pages: No page available

10.1161/jaha.121.024709 | PMID 35699175 Get It

Background TAILOR‐PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to decreased Clopidogrel Response After Percutaneous Coronary Intervention) studied genotype‐guided selection of antiplatelet therapy after percutaneous coronary intervention versus conventional therapy with clopidogrel. The presence of CYP2C19 loss‐of‐function alleles in patients treated with clopidogrel may be associated with increased risk for ischemic events. We report a prespecified sex‐specific analysis of genotyping and associated cardiovascular outcomes from this study. Methods and Results Associations between sex and major adverse cardiac events (MACE: cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia) and Bleeding Academic Research Consortium (BARC) bleeding at 12 months were analyzed using Cox proportional‐hazards models. Among 5276 randomized patients, loss‐of‐function carriers were observed in ≈36% of both sexes, and >80% of carriers were heterozygotes. At 12 months, after adjustment for baseline differences, risks of MACE (HR , 1.28 [0.97 to 1.68]; P =0.088) and BARC bleeding (hazard ratio [HR], 1.36 [0.91 to 2.05]; P =0.14) were comparable among women and men. There were no significant interactions between sex and treatment strategy for MACE interaction P value ( P int =0.59) or BARC bleeding ( P int =0.47) nor for sex and genotype (MACE P int =0.15, and BARC bleeding P int =0.60). Conclusions CYP2C19 loss‐of‐function alleles were present in ≈1 in 3 women and men. Women had similar adjusted risks of MACE and bleeding as men following percutaneous coronary intervention. Genotype‐guided therapy did not significantly reduce the risk of MACE or bleeding relative to conventional therapy for both sexes. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01742117.
Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort
Kelly, Cecilia R. , Saw, Jacqui‐Lyn , Thapa, Prabin , Mandrekar, Jay , Naddaf, Elie , Naddaf, Elie

Mayo Clinic

Muscle & Nerve | January 12, 2022 | Volume: 65 | Issue: 4 | Pages: 415-421

10.1002/mus.27493 | PMID 35020192 Get It

AbstractIntroduction/AimsThe full spectrum of the clinical phenotype of facioscapulohumeral muscular dystrophy (FSHD), beyond skeletal muscle weakness, remains poorly characterized. In this study, we describe systemic manifestations and symptom burden in a large series of FSHD patients.MethodsWe performed a retrospective chart review of FSHD patients seen at our institution between 2000 and 2017. We reviewed patients' responses to a comprehensive review of symptoms and the results of diagnostic testing for sensorineural hearing loss, cardiac disease, dysphagia, ocular abnormalities, and respiratory insufficiency. We assessed the association between disease manifestations and age of onset, genetic profile, and disease duration.ResultsWe identified 87 patients with FSHD. The most common reported symptoms included pain (71%), difficulty sleeping (41%), headaches (27%), and altered mood (24%). When tested, 7 of 16 (44%) patients had sensorineural hearing loss, 20 of 60 (33%) had cardiac arrhythmias or conduction defects, 17 of 45 (38%) had echocardiogram abnormalities, 12 of 25 (48%) had reduced forced vital capacity, and 4 of 10 (40%) had oropharyngeal dysphagia. However, patients with these abnormalities represented 8%, 23%, 20%, 14%, and 5% of total number of patients, respectively, as uniform screening was lacking. Ocular pathology attributable to FSHD was not detected.DiscussionFSHD demonstrates a broad clinical phenotype. Increased vigilance among neurologists to screen for systemic manifestations of the disease is warranted. More uniform screening and future population‐based studies are needed to compare findings in FSHD patients with the general population.
Intracardiac echocardiography for guidance of transcatheter left atrial appendage occlusion: An expert consensus document
Berti, Sérgio , Korsholm, Kasper , Saw, Jacqueline , Costa, Marco P., Odenstedt, Jacob, Packer, Erik JS, Tondo, Claudio , Santoro, Gennaro, Nielsen‐Kudsk, Jens Erik , Pastormerlo, Luigi E , Korsholm, Kasper , Saw, Jacqueline , Tondo, Claudio , Berti, Sergio , Alkhouli, Mohamad , Packer, Erik J. S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | June 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ccd.29791 | PMID 34086394 Get It